Statement: in the primary clinical trial, patients will not be allowed to continue the intervention protocol until they achieve either complete response or suffer disease progression
Primary_evidence: INTERVENTION 1:    Pemetrexed   600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression